There are 2789 resources available
1057P - ROS1 mutation can serve- as a potential efficacious predictor of immunotherapy in melanoma patients
Presenter: Hucheng Liu
Session: ePoster Display
1058P - Treatment outcomes with unselected autologous tumor infiltrating lymphocytes (TILs) in patients (pts) with checkpoint inhibition–refractory advanced cutaneous melanoma
Presenter: Manon Pillai
Session: ePoster Display
1059P - 18F-FDG-PET/CT response assessment in patients with advanced melanoma treated with combination of low-dose ipilimumab and anti-PD1: A real-world experience
Presenter: Caio De Liz
Session: ePoster Display
1060P - Serum metabolomic profiling reveals differences in polyamine and tryptophan metabolites in patients with cutaneous, mucosal and uveal melanoma
Presenter: Maysa Vilbert
Session: ePoster Display
1061P - Safety of cemiplimab for advanced cutaneous squamous cell carcinoma: The Spanish named patient programme
Presenter: Almudena Garcia Castano
Session: ePoster Display
Resources:
Abstract
1062P - Real-world data on clinical outcome and tolerability in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab in the Netherlands
Presenter: Maartje Rohaan
Session: ePoster Display
1063P - Real-world treatment patterns and outcomes of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) in the US
Presenter: Emily Ruiz
Session: ePoster Display
1011P - FORTITUDE phase I study of NG-350A, a novel tumour-selective adenoviral vector expressing an anti-CD40 agonist antibody: Monotherapy dose escalation results
Presenter: Aung Naing
Session: ePoster Display
1012P - Intratumoral immunotherapy with a novel TLR1/2/3 agonist, L-pampo, induces robust anti-tumor immune responses and enhances immune checkpoint blockade
Presenter: WON SUK LEE
Session: ePoster Display
1013P - Similar overall survival in tebentafusp-treated 2L+ metastatic uveal melanoma regardless of prior immunotherapy
Presenter: Josep M. Piulats
Session: ePoster Display